Foley Todd's Form 4 filing
Aktis Oncology, Inc.AKTS · filed Jan 14, 2026
- Accession no.
- 0001473930-26-000005
- Filed
- Jan 14, 2026
- Trade date
- Jan 12, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market purchases total $4.19M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Foley ToddCIK 0001473930 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | Common Stock | CConversionAcquired | +597,391 | –F2 | – | 597,391 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionAcquired | +2,688,270 | –F2 | – | 3,285,661 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionAcquired | +716,872 | –F2 | – | 4,002,533 | Indirect | |
| Jan 12, 2026 | Common Stock | PPurchaseAcquired | +232,870 | $18.00 | +$4,191,660 | 4,235,403 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | Common Stock | CConversionDisposed | −597,391 | $0.00F2 | $0 | 0 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionDisposed | −2,688,270 | $0.00F2 | $0 | 0 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionDisposed | −716,872 | $0.00F2 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date.
Referenced by the price of 3 transactions in Table I and 3 transactions in Table II.